FEEDS
FORXIGA® (dapagliflozin) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes
Paris And London (ots/PRNewswire) - Bristol-Myers Squibb Company [http://www.bms.com ] and AstraZeneca [http://www.astrazeneca.com/Home ] today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ... weiter zur Pressemitteilung von Bristol-Myers Squibb and AstraZeneca
KOMBOGLYZE(TM) Receives Marketing Authorisation in the European Union for Adult Patients With Type 2 Diabetes
Paris and London, November 29 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for KOMBOGLYZETM (saxagliptin and metformin HCl immediate-release fixed ... weiter zur Pressemitteilung von Bristol-Myers Squibb and AstraZeneca
/C O R R E C T I O N -- Bristol-Myers Squibb and AstraZeneca/
Paris and London (ots/PRNewswire) - In the news release, "ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe" issued on 4 Mar 2011 08:00 GMT, by Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like ... weiter zur Pressemitteilung von Bristol-Myers Squibb and AstraZeneca
ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe
Paris and London (ots/PRNewswire) - Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca.com) today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment ... weiter zur Pressemitteilung von Bristol-Myers Squibb and AstraZeneca
24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults With Type 2 Diabetes Mellitus
Stockholm (ots/PRNewswire) - Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca-us.com) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of ... weiter zur Pressemitteilung von Bristol-Myers Squibb and AstraZeneca
Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin
Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level ... weiter zur Pressemitteilung von Bristol-Myers Squibb and AstraZeneca
52-Week Study Finds ONGLYZA(TM) (saxagliptin) When Added To Metformin Was Non-Inferior To Titrated Glipizide When Added To Metformin In Reducing Glycosylated Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus
Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate glycemic control on metformin therapy plus ... weiter zur Pressemitteilung von Bristol-Myers Squibb and AstraZeneca
ONGLYZA(TM) (saxagliptin) With Metformin As Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control In Treatment-Naive Adults With Type 2 Diabetes
Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which ... weiter zur Pressemitteilung von Bristol-Myers Squibb and AstraZeneca
